



ADVANCES IN DIAGNOSTICS AND IMMUNOTHERAPEUTICS FOR NEURODEGENERATIVE DISEASES

Editors:

Anuradha Mishra

Preeti Bajpai

Tarique Mahmood Ansari

Bentham Books

Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases

Edited by

Anuradha Mishra

*Amity Institute of Pharmacy, Lucknow
Amity University Uttar Pradesh
Noida, 201313 (U.P.), India*

Preeti Bajpai

*Department of Zoology
Mahatma Gandhi Central University
Motihari-845401, Bihar
India*

&

Tarique Mahmood Ansari

*Department of Pharmacy
Integral University, Kursi Road Lucknow
226026, India*

Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases

Editors: Anuradha Mishra, Preeti Bajpai, and Tarique Mahmood Ansari

ISBN (Online): 978-981-5238-75-4

ISBN (Print): 978-981-5238-76-1

ISBN (Paperback): 978-981-5238-77-8

© 2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
INTRODUCTION	iv
LIST OF CONTRIBUTORS	v
CHAPTER 1 A SYSTEMATIC REVIEW OF NEURODEGENERATIVE DISEASES: ETIOLOGY, CLINICAL SYMPTOMS, PATHOGENESIS, AND FUTURE DEVELOPMENTS	1
<i>Satya Prakash Singh, Deepti Dwivedi, Rabiya Ahsan, Ankur Srivastava and Ajay Kumar Shukla</i>	
INTRODUCTION	1
Parkinson's Disease	3
Huntington's Disease	4
Alzheimer's Disorders	4
Amyotrophic Lateral Sclerosis (ALS)	4
Symptoms of Neurodegenerative Diseases	5
Neurodegeneration: Etiologies	7
Ageing: Relevant to the Growth of Neurodegenerative Disorders	9
Neurodegenerative Disorders Caused by Mitochondrial Dysfunction	10
Recent Treatments of Cognitive Impairments	10
Pathologies that Mitochondrial DNA Mutations may Cause	11
CONCLUSION AND FUTURE DEVELOPMENTS	12
ABBREVIATIONS	12
REFERENCES	13
CHAPTER 2 NEURO-INFLAMMATORY RESPONSES IN ALZHEIMER'S V/S PARKINSON'S DISEASES	17
<i>Amrutha K. and Sarika Singh</i>	
INTRODUCTION	17
INFLAMMATORY RESPONSES IN ALZHEIMER'S DISEASE	19
INFLAMMATORY RESPONSES IN PARKINSON'S DISEASE	20
APPLICATION OF NEUROINFLAMMATORY RESPONSES FOR DISEASE DIAGNOSIS	21
TUMOR NECROSIS FACTOR-A (TNF-A)	21
INTERLEUKIN-1B (IL-1B)	22
NITRIC OXIDE (NO)	22
CYCLOOXYGENASE- 2 (COX-2)	22
INTERFERONS (IFNS)	23
ASTROCYTES	23
UTILIZATION OF NEUROINFLAMMATORY RESPONSES FOR THERAPEUTICS	24
CONCLUSION	26
REFERENCES	26
CHAPTER 3 IMMUNOPATHOGENESIS OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AND OTHER NEURODEGENERATIVE DISEASES	32
<i>Sunil Kumar, Ajay Kumar Shukla, Vimal Kumar Yadav, Ankur Srivastava, Deepti Dwivedi and Satya Prakash Singh</i>	
INTRODUCTION	33
Worldwide Data of AD	34
<i>Pathophysiology of Immunopathogenic Neurodegenerative Disease Hypotheses</i>	34

AMYLOID-B HYPOTHESIS	35
Protein Aggregation	36
CHOLINERGIC HYPOTHESIS	37
METAL HYPOTHESIS	38
TAU PROTEIN HYPOTHESIS	39
Toxic Oligomer' Hypothesis	40
Protein Homeostasis Hypothesis (Protein (Mis) Folding)	41
Dissents and Molecular Chaperones	41
Protein Misfolding and Endoplasmic Reticulum Stress	41
Unfolded Protein Response (UPR)	42
Interaction of Proteins	43
Autophagy and Neurodegeneration	43
UPS in Neurodegenerative Disorders	43
Aggresomes	44
OXIDATIVE STRESS	44
Metals and Oxidative Stress	45
Oxidative Stress in Other Neurodegenerative Disorders	45
IMPAIRED MITOCHONDRIAL DYSFUNCTION HYPOTHESIS	45
FRAGMENTATION OF NEURONAL GOLGI HYPOTHESIS	46
DISRUPTION OF CELLULAR/AXONAL TRANSPORT DYSREGU- LATION HYPOTHESIS	46
Axonal Transport in Other Neurodegenerative Diseases	47
DYSFUNCTION OF NEUROTROPHINS HYPOTHESIS	47
NEUROINFLAMMATORY HYPOTHESIS	48
THE ROLE OF CHEMOKINES IN NEURODEGENERATIVE DISEASES (NDD) HYPOTHESIS	48
CCL2 (Monocyte Chemoattractant Protein)	49
Human Macrophage Inflammatory Protein 1 α (CCL3)	49
CXCL8 (Interleukin 8)	50
CXCL12 (Stromal Cell–Derived Factor 1)	50
CX3CL1 (Fractalkine)	50
MULTIFACETED NEURONAL DEATH HYPOTHESIS	51
Cell Death Cascades in NDDs	52
THE IMMUNOPATHOGENESIS OF GUT MICROBIOTA HYPOTHESIS	52
Gut Microbiota Responsible for Neurodegenerative Diseases	53
Gut Microbiota Impact on Immune System and Neuroinflammation	53
Gut Microbiota Impact on Activities	53
NEUROTRANSMITTERS HYPOTHESIS	53
NEW INSIGHTS PATHOGENESIS	54
Gamma Oscillations Ameliorate Pathology and Cognitive Impairment in AD	54
A β and Tau Prions Spread Through the Brains of AD Patients	55
A β Interact with Hippocampal Ghrelin/GHSR1 α Signaling in AD	55
A β Constrict Cerebral Capillaries in AD Pathology	56
CONCLUSION	57
AUTHOR CONTRIBUTIONS	57
REFERENCES:	57
CHAPTER 4 IMMUNOBIOLOGY AND IMMUNOTHERAPIES IN HUNTINGTON'S DISEASE	65
<i>Artatrana Pal, Golden Kumari and Sonu Kumar</i>	
INTRODUCTION	65

IMMUNE SYSTEM AND BRAIN	66
Immune System and HD brain	67
Mechanisms of Neurodegeneration in HD	67
Clinical Features in HD	68
Immune Complement System in HD	69
Pathways of the Complement System and Cytokines in HD	69
Neuro-inflammation and Neurodegeneration in HD	70
ROLE OF INNATE AND ADAPTIVE IMMUNE RESPONSES IN HD	72
Role of Microglia	72
mHTT and Inflammation	74
Monocytes and Macrophages in HD	75
Complement System	75
IL-6	75
IL-1 β	76
TNF- α	76
TLRs	77
Mast Cells	77
ROLE OF ADAPTIVE IMMUNE RESPONSES IN HD	77
Dendritic Cells	78
T Cells	78
IL-4	78
Immune Treatment for HD	79
IMMUNOMODULATORY DRUGS FOR HD	79
Drugs for Chorea in HD	79
<i>Tetrabenazine</i>	79
<i>Deutetrabenazine</i>	79
<i>Dopamine Antagonists</i>	80
Anti-glutamatergic	80
Antipsychotic Medication	80
More Drugs for HD	80
<i>Laquinimod</i>	80
<i>Anti-semaphorin 4D</i>	81
<i>Anti-TNF-α Therapy</i>	81
Immunotherapies for mHTT	81
Antibody-based Therapy for HD	82
Indirect Therapies Helpful for HD Subjects Along with Immunotherapy	82
<i>Speech Therapy</i>	82
<i>Physical Therapy and Establishing a Routine Activity</i>	82
<i>Supplements for HD</i>	83
Future Perspectives	83
CONCLUSION	84
REFERENCES	84
CHAPTER 5 INTRODUCTION TO GUT MICROBIOTA AND THEIR EFFECTS ON VARIOUS BRAIN DISORDERS	88
<i>Afreen Usmani and Anuradha Mishra</i>	
INTRODUCTION	88
EFFECTS OF INTESTINAL MICROBIOME-BASED THERAPIES ON NEURODEGENERATIVE DISEASES	92
Alzheimer's Disease (AD)	92
Parkinson's Disease (PD)	94

Amyotrophic Lateral Sclerosis (ALS)	95
Huntington's Disease (HD)	95
Neurodegenerative Diseases and Short Chain Fatty acids (SCFAs)	96
CONCLUSION	97
Future Perspective	97
ACKNOWLEDGEMENT	99
REFERENCES	99
CHAPTER 6 INTERPLAY BETWEEN GUT-MICROBIOTA AND NEURODEGENERATION	104
<i>Sumel Ashique, Radheshyam Pal, Shubneesh Kumar, Bharti Verma, Nitish Kumar, Ivan Kahwa, Arshad Farid, Neeraj Mishra, Prashant Kumar and Farzad Taghizadeh-Hesary</i>	
INTRODUCTION	105
GUT MICROBIOTA	106
Gut Microbiota and Neurodegenerative Disease: A Correlation	106
BRAIN AND GUT MICROBIOTA COMMUNICATIONS	107
Gut-Brain Axis	107
Blood-Brain Barrier and Molecules Derived from the Gut	108
Central Nervous System Modifications	109
Modification of Immune System	109
A NEW PARTICIPANT IN NEURODEGENERATIVE DISEASES: GUT MICROBIOTA:	
CNS HOMEOSTASIS	110
Microbiome's Role in Alzheimer's Disease (AD)	111
Microbiome's Role in Parkinson's Disease	112
Microbiome's Role in Huntington's Disease	113
Microbiota Implicates Internal Factor - Influence on Multiple Sclerosis	113
Gut Microbiota and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia	114
Gut Microbiota and Various Different Forms of Dementia	115
GUT MICROBIOME, OXIDATIVE STRESS, AND NEURODE- GENERATION	117
GUT MICROBIOME IN NEUROPROTECTION	119
Gut Microbiome Metabolites for Neuroprotection with their Cell-specific Responses	121
<i>Gut Microbiome Interaction with Specific Host Molecules</i>	121
<i>Interaction between Dietary Molecules and Gut Microbiome</i>	122
ASSESSING THE IMPACT OF GUT MICROBIOTA ON BRAIN	
NEURODEGENERATION USING EXPERIMENTAL MODELS	125
Systems for Continual Gut Microbiota Culture	125
<i>Simulator of the Human Intestinal Microbial Ecosystem (SHIME)</i>	126
<i>TNO Gastro-Intestinal Model (TIM)</i>	126
<i>Dynamic Gastro-Intestinal Simulator (SIMGI)</i>	127
CONCLUSION	128
ACKNOWLEDGMENT	128
REFERENCES	129
CHAPTER 7 EPIGENETIC REGULATION OF MICROGLIA: PLAUSIBLE MECHANISM	
AND INTERVENTIONAL APPROACHES IN NEURODEGENERATION	146
<i>Sameen Shafi, Hafizur Rahman Khan and Preeti Bajpai</i>	
INTRODUCTION	146
Origin of Microglia	147
Microglial Polarization Phenotype	149
MICROGLIAL FUNCTIONS	151
Maintenance of Synapses	151
Synaptic Pruning	151

Regulating Nerve Network	152
Neurotransmitter Receptors on Microglia	152
EPIGENETIC REGULATION OF MICROGLIA	153
Histone Acetylation	153
Histone Methylation	154
DNA Methylation	156
Epigenetic Crosstalk	156
CONCLUSION	157
REFERENCES	157
CHAPTER 8 EPIGENETICS AS DIAGNOSTIC AND THERAPEUTIC TOOL IN NEURODEGENERATIVE DISORDERS	162
<i>Rufaida Wasim, Tarique Mahmood, Farogh Ahsan, Aditya Singh and Asad Ahmad</i>	
INTRODUCTION	162
EARLY DIAGNOSIS AND TREATMENT	164
NEURODEGENERATIVE DISORDERS AND EPIGENETIC ALTE- RATION	164
POTENTIAL EPIGENETIC THERAPEUTIC INTERVENTION TARGETS	166
Inhibitors of DNA Methylation and DNA Methyltransferases (DNMT)	166
Histone Acetylation and Histone Deacetylases (HDAC) Inhibitors	167
NEURODEGENERATIVE DISORDERS TREATMENT	169
Alzheimer's Disease	169
Parkinson's Disease	170
Huntington's Disease	171
CONCLUSION	172
ACKNOWLEDGMENT	172
REFERENCES	172
CHAPTER 9 CURRENT THERAPEUTIC OPTIONS AND REPURPOSED DRUGS FOR NEURODEGENERATION	177
<i>Suneela Dhaneshwar, Mohammad Aadil Bhat, Anuradha Singh and Supriya Roy</i>	
INTRODUCTION	177
Drug Repurposing	178
ALZHEIMER'S DISEASE (AD)	179
DRUG REPURPOSING FOR AD	180
Anti-cancer Agents	180
<i>Epidermal Growth Factor Receptor Inhibitors (EGFRI)</i>	180
<i>Tyrosine Kinase Inhibitors</i>	181
Retinoid X Receptor (RXR) Agonists	183
Miscellaneous Drugs	183
Antidiabetic Drugs	184
<i>Hypoglycaemic Agents</i>	184
<i>Anti-hyperglycaemic Drugs</i>	185
Antihypertensive Drugs	186
Antiepileptic Drugs	187
Phosphodiesterase-5 Inhibitors	187
PARKINSON'S DISEASE (PD)	188
Drug Repurposing for PD	189
<i>Exenatide</i>	189
<i>Nilotinib</i>	189
<i>Terazosin</i>	190
<i>Simvastatin</i>	190
<i>Ursodeoxycholic Acid</i>	191

ISRADIPINE	191
HUNTINGTON'S DISEASE (HD)	192
Drug Repurposing for HD	192
<i>Tetrabenazine</i>	192
<i>Olanzapine</i>	193
<i>Memantine</i>	193
<i>Risperidone</i>	193
<i>Quetiapine</i>	194
<i>Amantadine</i>	194
<i>Statins</i>	194
FRIEDREICH ATAXIA (FRDA)	195
Drug Repurposing	195
<i>Dyclonine</i>	195
<i>Diazoxide</i>	195
<i>Dimethyl Fumarate</i>	196
<i>Etravirine</i>	196
<i>PPAR-γ Agonist</i>	197
SPINAL MUSCULAR ATROPHY (SMA)	197
Drug Repurposing for SMA	198
<i>Riluzole and Rasagiline</i>	198
<i>Masitinib</i>	198
<i>Amifampridine</i>	199
<i>Celecoxib and Hydroxyurea</i>	199
<i>Salbutamol</i>	200
AMYOTROPHIC LATERAL SCLEROSIS (ALS)	200
Drug Repurposing for ALS	201
<i>Ezogabine</i>	201
<i>Memantine</i>	201
<i>Masitinib</i>	202
<i>Rasagiline</i>	202
<i>Mexiletine</i>	202
<i>Ibudilast</i>	203
<i>Triumeq</i>	203
CONCLUSION	203
REFERENCES	204
SUBJECT INDEX	442

FOREWORD

Neurodegenerative conditions, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis, are debilitating disorders that affect millions of people worldwide. These conditions are characterized by the progressive loss of function and death of neurons, resulting in a wide range of symptoms, including memory loss, motor impairment, and cognitive decline. Despite extensive research, there is currently no cure for most neurodegenerative conditions, and existing treatments only offer limited symptom relief.

However, there is a ray of hope. In recent years, significant advances have been made in the field of neurodegenerative research, particularly in the areas of diagnostics and immunotherapy. These advances have led to the development of novel diagnostic tools that allow for earlier and more accurate diagnosis of these conditions, as well as promising immunotherapeutic approaches that target the underlying pathologies of these diseases.

This book, *Advances in Diagnostic and Immunotherapeutic Approaches for Neurodegenerative Conditions*, provides a comprehensive overview of these recent advances, highlighting the most promising developments and providing insights into future directions for research and treatment.

The book focuses on advances in diagnostics, covering topics such as biomarkers for early detection, imaging techniques for improved diagnosis, and the role of genetics in neurodegenerative conditions. The authors explore the potential of these diagnostic tools to enhance early detection and diagnosis, which is crucial for the development of effective treatments, and immunotherapeutic approaches, including novel strategies for targeting misfolded proteins and inflammatory pathways, as well as the use of stem cells and gene therapy. The authors explore the potential of these approaches to slow or even reverse the progression of neurodegenerative conditions, offering hope for the development of effective disease-modifying treatments.

The final section of the book examines the challenges and opportunities presented by these recent advances, exploring topics such as ethical considerations in the development and implementation of these approaches, the potential impact on healthcare systems, and the need for collaboration between researchers, clinicians, and patients.

This book is an essential resource for researchers, clinicians, and students in the fields of neurology, neuroscience, and immunology, as well as for anyone interested in the latest developments in the diagnosis and treatment of neurodegenerative conditions.

Overall, the book “*Advances in Diagnostic and Immunotherapeutic Approaches for Neurodegenerative Conditions*” represents an important contribution to the field of neurodegenerative research, offering a roadmap for the development of more effective diagnostic and therapeutic approaches, and providing hope for a brighter future for those living with these conditions.

Dr. Rakesh Kumar Dixit
Pharmacology and Therapeutics
King George Medical University
Lucknow, India

PREFACE

In the intricate landscape of neuroscience, the journey to understanding and combating neurodegenerative conditions has been both challenging and inspiring. "Advances in Diagnostic and Immunotherapeutic Approaches for Neurodegenerative Conditions" endeavors to capture the remarkable strides made in recent years, offering readers a panoramic view of the cutting-edge research shaping the future of neurodegenerative disease management.

Neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), represent a complex and multifaceted challenge. These conditions not only affect the individuals diagnosed but also reverberate through families, communities, and healthcare systems worldwide. With the aging population on the rise, the imperative to develop effective diagnostic tools and therapeutic strategies has never been more pressing.

This comprehensive book aims to provide readers with a panoramic view of the latest advancements in diagnostic methodologies, from cutting-edge imaging technologies and biomarker identification to sophisticated genetic profiling techniques. By illuminating these breakthroughs, we strive to enhance our understanding of disease mechanisms, enabling earlier detection, more accurate diagnosis, and personalized treatment approaches.

The latter sections of the book are dedicated to exploring the burgeoning field of immunotherapeutic interventions. Here, we delve into the exciting potential of harnessing the body's immune system to target and combat neurodegenerative processes. The latter chapters in this section showcase the transformative power of immunotherapy in reshaping our approach to treating neurodegenerative conditions.

However, this volume is not merely a compilation of scientific achievements; it is a call to action. By highlighting the most promising developments and discussing the challenges that remain, we hope to inspire collaboration and innovation across disciplines. The complex nature of neurodegenerative research necessitates a multidisciplinary approach, where insights from neuroscience, immunology, genetics, and computational biology converge to drive progress.

As you navigate through the pages of "Advances in Diagnostic and Immunotherapeutic Approaches for Neurodegenerative Conditions," you will encounter the dedication, perseverance, and vision of the scientists, clinicians, and researchers who are leading the charge against neurodegeneration. Their pioneering work, presented here in detail, offers a compelling narrative of hope, resilience, and the relentless pursuit of scientific excellence.

We invite you to embark on this enlightening journey with us, as we explore the present landscape and envision a brighter, healthier future for those affected by neurodegenerative conditions.

Anuradha Mishra

Amity Institute of Pharmacy, Lucknow
Amity University Uttar Pradesh
Noida, 201313 (U.P.), India

Preeti Bajpai

Department of Zoology
Mahatma Gandhi Central University
Motihari-845401, Bihar
India

&

Tarique Mahmood Ansari

Department of Pharmacy
Integral University, Kursi Road Lucknow
226026, India

INTRODUCTION

In this book, various categories of neurodegenerative conditions are discussed, along with their pathological origins, which include genetic and epigenetic factors, and different therapies such as synthetic drugs, biologicals, and repurposed drugs. The book is divided into three segments.

The first segment covers different categories of neurodegenerative conditions (NDC) and their pathological states of origin. It delves into neuroinflammation and its role in causing Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and more. Furthermore, it covers how such inflammatory responses can be held responsible for the generation of NDC. Interestingly, it also sheds light on how such inflammatory pathways open the door to impending therapy and next-generation drug development. This segment also covers immunomodulation associated with degenerative Huntington's disease. The second segment focuses on gut microbiota and their impact on the genesis of brain disorders. It discusses the interplay between gut microbiota and neurodegeneration. The third segment discusses epigenetics and its potential role in intervening in neurodegeneration. Finally, the book explores the use of repurposed drugs in treating NDDs.

List of Contributors

Anuradha Singh	Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida, India
Asad Ahmad	Department of Pharmacy, Integral University, Lucknow, India
Aditya Singh	Department of Pharmacy, Integral University, Lucknow, India
Arshad Farid	Gomal Center of Biochemistry and Biotechnology, Gomal University, D.I.Khan, KPK, Pakistan
Anuradha Mishra	Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida, 201313 (U.P.), India
Afreen Usmani	Department of Pharmacology, MESCO Institute of Pharmacy, Amroha 244221, India
Artatrana Pal	Department of Zoology, School of Life Sciences, Mahatma Gandhi Central University, Bihar, India
Ankur Srivastava	Institute of Pharmacy, Dr. Ram Manohar Lohia Avadh University, Ayodhya, India
Ajay Kumar Shukla	Institute of Pharmacy, Dr. Ram Manohar Lohia Avadh University, Ayodhya, India
Amrutha K.	Division of Toxicology and Experimental Medicine , CSIR-Central Drug Research Institute, Lucknow, India
Ajay Kumar Shukla	Institute of Pharmacy, Dr. Ram Manohar Lohia Avadh University Ayodhya, Ayodhya, India
Deepti Dwivedi	Institute of Pharmacy, Dr. Shakuntala Misra National Rehabilitation University, Lucknow, India
Deepti Dwivedi	Institute of Pharmacy, Dr. Shakuntala Misra National Rehabilitation University, Lucknow, India
Farzad Taghizadeh-Hesary	Assistant Professor, ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Iran
Farogh Ahsan	Department of Pharmacy, Integral University, Lucknow, India
Golden Kumari	Department of Zoology, School of Life Sciences, Mahatma Gandhi Central University, Bihar, India
Hafizur Rahman Khan	Department of Zoology, Maharani Janki Kunwar College, Bettiah-845438, Bihar, India
Ivan Kahwa	Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda
Preeti Bajpai	Department of Zoology, Mahatma Gandhi Central University, Motihari-845401, Bihar, India
Radheshyam Pal	Department of Pharmaceutics, Pandaveswar School of Pharmacy, Pandaveswar, West Bengal, India
Rufaida Wasim	Department of Pharmacy, Integral University, Lucknow, India

Rabiya Ahsan	Research Scholar, Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India
Mohammad Aadil Bhat	Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida, India
Neeraj Mishra	Department of Pharmaceutics, Amity Institute of Pharmacy, Gwalior, India
Nitish Kumar	SRM Modinagar College of Pharmacy, SRM Institute of Science and Technology (Deemed to be University), Delhi-NCR Campus, India
Prashant Kumar	Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, Uttar Pradesh, India
Supriya Roy	Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida, India
Suneela Dhaneshwar	Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai, India
Sameen Shafi	Department of Zoology, Mahatma Gandhi Central University, Motihari-845401, Bihar, India
Satya Prakash Singh	Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow, India
Sarika Singh	Division of Toxicology and Experimental Medicine , CSIR-Central Drug Research Institute, Lucknow, India
Sumel Ashique	Department of Pharmaceutics, Pandaveswar School of Pharmacy, Pandaveswar, West Bengal, India
Sunil Kumar	Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, India
Sonu Kumar	Department of Zoology, School of Life Sciences, Mahatma Gandhi Central University, Bihar, India
Satya Prakash Singh	Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow, India
Shubneesh Kumar	Department of Pharmaceutics, Bharat Institute of Technology, School of Pharmacy, Meerut, India
Tarique Mahmood	Department of Pharmacy, Integral University, Lucknow, India

CHAPTER 1

A Systematic Review of Neurodegenerative Diseases: Etiology, Clinical Symptoms, Pathogenesis, and Future Developments

Satya Prakash Singh^{1,*}, Deepti Dwivedi², Rabiya Ahsan³, Ankur Srivastava⁴ and Ajay Kumar Shukla⁴

¹ Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow, India

² Institute of Pharmacy, Dr. Shakuntala Misra National Rehabilitation University, Lucknow, India

³ Research Scholar, Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India

⁴ Institute of Pharmacy, Dr. Ram Manohar Lohia Avadh University, Ayodhya, India

Abstract: Neurodegenerative diseases (NDDs) are nervous system disorders that impact around 30 million people globally. Loss of brain tissue is a hallmark symptom of NDDs. Amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Parkinson's disease, Alzheimer's disease, and Huntington's disease are among the NDDs caused by protein misfolding and inappropriate processing of proteins. In addition, neurodegeneration has also been linked to oxidative stress, mitochondrial malfunction, and/or environmental variables strongly correlated with aging. Significant evidence has been obtained after years of intensive research that shows these factors have a crucial role in the etiology of prevalent neurodegenerative disorders. Many clues have been identified regarding neurodegenerative illnesses, but the complexities of these conditions still make them difficult to understand. This chapter presents a more straightforward explanation to help individuals better understand NDDs, their etiology, clinical symptoms, and pathogenesis

Keywords: Ageing, Neurodegenerative diseases, Neurodegenerative disorders, Neurodegeneration, Parkinson's disease.

INTRODUCTION

There is an immediate danger to human health from neurodegenerative illnesses. The ageing of the population has led to an increase in cases of neurodegenerative illnesses such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral

* Corresponding author Satya Prakash Singh: Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow, India; E-mail: singh.satyaprakashh@gmail.com

sclerosis (ALS), frontotemporal dementia, and spinocerebellar ataxias. The pathophysiology of these conditions is quite diverse; some of them manifest in memory and cognitive decline, while others manifest in difficulties with locomotion, speech, and respiration [1, 2]. Just to name a few, there are (a) Aberrant protein dynamics with faulty protein aggregation and degradation, (b) Oxidative stress and the formation of free radicals, (c) Poor bioenergetics and dysfunctional mitochondria, and (d) Exposure to pesticides and metal toxicity (Fig. 1). In addition, despite extensive research efforts, the pathophysiology of these proteinopathies remains unclear, making it difficult to identify effective therapeutic drug targets. However, neuroscientists have capitalized on their comprehension of the primary etiology of these disorders to study applications with the aim of producing recently developed new therapeutics for these diseases. Even though every disease has a unique molecular mechanism and set of clinical symptoms, certain common pathways may be identified in various pathogenic cascades. These include oxidative stress and free radical production, metal dyshomeostasis, mitochondrial dysfunction, protein misfolding and aggregation, and phosphorylation impairment, all occurring concurrently.




Fig. (1). Different factors responsible for the precipitation of neurodegenerative disorders [7].

With remarkable progress in genome sequencing technology, we can now read individual genomes and get insight into the origins of both common and unusual genetic illnesses, although Deoxyribonucleic acid (DNA) sequence variants are common, it is not yet known which ones are harmful and only cause a slight change in gene function [3]. Human genome sequencing has led to the identification of candidate gene variants, the effects of which may be evaluated using model animals. A cure for spinal muscular atrophy (SMA) is an inspiring example of scientific advancement. Mutations causing loss of function in the

survival motor neuron (SMN1) gene result in SMA, the most common inherited cause of infant mortality. On the heels of ground-breaking research into the molecular basis of the disease and the development of animal models, antisense oligonucleotides (ASOs) are currently being tested in human trials as a therapy option to correct a splicing error and restore functional SMN protein. Researchers verified the promising findings in animal model systems in two clinical trials, including children with SMA. After the approval by the Food Drug Administration (FDA) of the ASO medication at the year's end, it became the first disease-modifying therapy for SMA and a comparison was made between infants who did not receive the medication with those who showed significant gains in motor ability. This is a big win for patients, their loved ones, and the model systems [4].

The healing path forward in the fight against neurodegenerative diseases is now clear. Scientists studying this field are fortunate to be doing their work during such an intriguing and productive time [5, 6]. The primary target of neurodegeneration, which has a multifactorial aetiology, is the neurons in the human brain. This disorder is linked to the gradual loss of brain tissues, which results in the death of neurons. It is directly related to ageing, and one of its primary characteristics is the degeneration of proteins, which leads to the buildup of inclusion bodies and insoluble deposits in different parts of the brain. Neurotoxic oligomers, oxidative stress, neuroinflammation, mitochondrial dysfunction, calcium dysregulation, deficiencies in axonal transport, metal buildup, amyloid deposition, and DNA damage are only a few other factors that have been associated with neurodegeneration (Fig. 1). Through a variety of pathways, including apoptosis, necrosis, autophagy, and parthanatos, programmed cell death eventually results from the persistence of these conditions overwhelming self-defense mechanisms.

Parkinson's Disease

Neurodegenerative diseases include Parkinson's. When substantia nigra neurons die, movement issues occur. The substantia nigra contains many neurons that produce dopamine. Substantia nigra neurons release dopamine to connect with movement-producing brain regions like the frontal lobe and basal ganglia. Ganglia are neuron clusters. Basal ganglia are neuronal groupings in the brain's core. Neuronal loss in the substantia nigra causes stumbling and trembling in persons with this condition. They have trouble initiating and maintaining movement [7].

CHAPTER 2**Neuro-inflammatory Responses in Alzheimer's v/s Parkinson's Diseases****Amrutha K.¹ and Sarika Singh^{1,2,*}**¹ *Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow-226031, India*² *Academy of Scientific & Innovative Research (AcSIR), Ghaziabad-201002, India*

Abstract: Neurodegenerative diseases are a heterogeneous group of disorders and are the leading cause of morbidity and disability. These are described by the progressive degeneration of the neurons and impaired function of the central nervous system. Prevailing neurodegenerative diseases in the world include Alzheimer's disease and Parkinson's disease and reports predict that on average, the prevalence of both diseases will double in a span of the next twenty years. Pieces of evidence showed that the immune system is profoundly involved in brain development, maintenance, and repair as well as in damage, therefore, may provide a wide scope to focus on the neuroinflammation-based therapeutic approaches. In this chapter, the various neuroinflammatory responses will be discussed during the onset and progression of both Alzheimer's and Parkinson's disease pathologies. We will be focusing on both central and peripheral inflammatory responses and their consideration for disease diagnosis and therapeutics.

Keywords: Alzheimer's disease, Disorders, Neuroinflammation, Parkinson's, Pathologies.

INTRODUCTION

Inflammation is a crucial physiological event in response to infection, injury, and trauma. An effective inflammatory response mechanism eradicates invading pathogens and initiates cellular healing. Neuroinflammatory responses particularly involve the inflammatory responses of cells available in the brain and spinal cord. Such inflammatory responses are mediated by the production of cytokines (IL-1 β , TNF α , and IL-6), chemokines (CCL5, CCL2, CXCL1), reactive oxygen species, and secondary messengers (NO and prostaglandins). These mediators are mostly produced by glial cells of the brain (microglia and

* **Corresponding author Sarika Singh:** Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India; E-mail: sarika_singh@cdri.res.in

astrocytes), endothelial cells, and peripheral-derived immune cells which collectively may execute various immune, physiological, biochemical, and psychological responses [1, 2]. In such a framework, the inflammation can be noticed as an intricate series of localized immune responses that collectively serve to deal with various menaces to the brain microenvironment. In most neurodegenerative diseases, inflammatory responses are unavoidable and significantly contribute to disease onset and progression. The observed neuroinflammatory responses may be the initiators or the consequences of the dying neurons however, the sequential events are still not known. In the central nervous system (CNS), the resident glial cells (microglia and astrocytes) play a crucial role in the neuroinflammatory responses during disease conditions, and among these, microglial cells have more deleterious effects as these are the phagocytic cells of the brain. On the contrary, the astrocytes protect the neurons by facilitating their antioxidant defenses through the glutathione pool. Astrocytes also provide metabolic support to neurons and constitute the only energy reservoir for neurons as neurons cannot store glycogen [3]. Astrocytes also contribute to the maintenance of brain homeostasis including various aspects like ion concentration, pH of brain environment, and neurotransmitter concentrations in synaptic interstitial fluid. The tripartite synapse which comprises both presynaptic and postsynaptic neurons along with astrocyte contribution is the best example of a close functional association of neurons and astrocyte's physiology [4, 5].

Microglial cells are brain resident M1 type phagocytic cells, which are actively involved in the maintenance of the brain microenvironment. Resting microglia represent ramified morphology and small while activated microglia represent amoeboid morphology have a retracted process and are comparatively big. In physiological conditions, the resting microglia and neurons communicate optimally and regulate the behavior and brain physiology mostly through CX3CL1 (fractalkine receptor) secreted from the neurons and its receptor located on microglial cells (CX3CR1) [6]. The interaction of Fractalkine and CX3CR1 initiates the signaling pathway which modulates the microglial activation in a broad spectrum. In both Alzheimer's and Parkinson's disease, the disruption of this interaction has been reported suggesting its active involvement in brain pathology [6, 7]. Though a contradictory report by Lee et al. (2010) has shown that the deficiency of receptor CX3CR1 decreases the microglia activation as well as declines the production of proinflammatory molecules (IL-1 β , TNF- α , monocyte chemoattractant protein 1 (MCP-1 or CCL2) and enhances its phagocytic activity which contributes to the reduction of β -amyloid protein accumulation [8]. Therefore, this suggests that both neurotoxic and neuroprotective actions of these signaling pathways are dependent on the disease stage, pathological context, and the stimuli that activate microglial cells in the CNS microenvironment. However, the reports suggest the critical role of both

microglial and astrocyte cells in the maintenance of physiological as well as pathological conditions by executing neuroinflammatory responses during injury or diseased conditions. In the next sections, we will discuss neuroinflammatory responses reported in the pathologies of Alzheimer's and Parkinson's disease.

INFLAMMATORY RESPONSES IN ALZHEIMER'S DISEASE

Astrocytes and microglia are the primary immune responses involved in the pathological process of AD [9]. The A β toxicity can be propagated by the microglia and astrocytes. A β aggregates can release cytokines, chemokines, nitric oxides, and ROS that contribute to neuronal death [10]. Aggregates of A β activate the microglia and it became referred to as disease-associated microglia that release several inflammatory factors. The activation of microglia was mainly due to the binding of A β on RAGE, nucleotide-binding oligomerization domain-like receptor (NLRs), and TLR 4 receptors that activate transcriptional factors such as NF- κ B, AP-1, c-AMP response element-binding protein and interferon regulating families. The activated microglia in turn play a role in the progression of AD [11]. The observed augmented immunoreactivity of microglia vicinal to A β plaques toward cytokines and chemokine receptors has been reported [12]. Along with microglial cells, astrocytes maintain homeostasis and provide growth factors to neurons. In AD condition, the astrocyte undergoes morphological and functional changes which make it a reactive astrocyte. These reactive astrocytes have increased expression of glial fibrillary acidic protein (GFAP) and have been found in the vicinity of A β plaque [13]. Astrocytes can also sense the A β aggregates in a TLR/RAGE-dependent manner and produce neurotoxic factors (IL1 β , TNF- α , IFN γ , IL6) [14].

In AD patients, IL-1 promotes the synthesis of inflammation-associated factors such as S100 β in astrocytes. Another report states that in A β diffuse deposits, IL-1 initiates dystrophic neurite formation and increases IL-1 level in AD patients promoting p38-MAP kinase activity, which leads to tau hyperphosphorylation [15]. It has also been emphasized that blocking of IL-1 β signaling decreases the GSK-3 β activity and promotes neurogenesis through the Wnt/ β -catenin pathway. Another report showed that cytokine IL-6 induces tau phosphorylation through cdk5/p35 pathway deregulation that leads to the formation of neurofibrillary tangles. Overexpression of IL-6 was observed in the brain of two hAPP transgenic models (TgCRND8 and Tg2576) that lead to significant gliosis that could promote A β elimination in early stages of the disease by upregulating microglial phagocytic marker [16]. It has been reported that TGF- β , a cytokine with anti-apoptotic function may promote neuronal survival [17]. In AD patients, the augmented level of TGF- β 1 was observed and it has been hypothesized that TGF- β 1 overexpression induces amyloidogenesis in the cerebral vasculature and

Immunopathogenesis of Alzheimer's disease, Parkinson's Disease, and other Neurodegenerative Diseases

Sunil Kumar¹, Ajay Kumar Shukla², Vimal Kumar Yadav², Ankur Srivastava², Deepti Dwivedi³ and Satya Prakash Singh^{1,4,*}

¹ Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, India

² Institute of Pharmacy, Dr. Ram Manohar Lohia Avadh University Ayodhya, Ayodhya, India

³ Institute of Pharmacy, Dr. Shakuntala Misra National Rehabilitation University, Lucknow, India

⁴ Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow, India

Abstract: Neurodegenerative diseases are categorized mostly by protein deposits or known hereditary mechanisms, despite recent studies showing overlap and intra-individual variations in these symptoms. A synergistic interaction between pathological proteins advises extensive pathogenic pathways. Animal models and other studies have uncovered the fundamental mechanisms underlying neurodegeneration and cell death, opening up new avenues for future prevention and therapy plans. A multidomain therapy approach that emphasizes the underlying reasons why diseases like Parkinson's, Alzheimer's, *etc.* occur. Neurodegenerative diseases like Parkinson's disease (PD) and Alzheimer's disease (AD) are becoming far more common in the Western world. Neuronal inflammation, gut microbiota, extracellular misfolded protein accumulation, hallmarks of various neurodegenerative nephropathies, and failure of the systemic and cerebral immune systems are some of the elements that affect the immunopathogenesis of neurodegenerative diseases. Deficits in the ubiquitin proteasome autophagy system, abnormal protein dynamics brought on by oxidative stress and free radical formation, mitochondrial dysfunction, impaired bioenergetics, neurotrophins dysfunction, “neuroinflammatory” processes, and (secondary) distractions of neuronal Golgi apparatus and axonal passage are some of the fundamental mechanisms that contribute to immunopathogenesis. Long-term cooperation between these interconnected systems results in programmed cell death. In this review, we discussed every idea and hypothesis that have been put up on the pathophysiology of neurodegenerative disorders.

* Corresponding author Satya Prakash Singh: Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow, India; E-mail: singh.satyaprakashh@gmail.com

Anuradha Mishra, Preeti Bajpai, and Tarique Mahmood Ansari (Eds.)
All rights reserved-© 2024 Bentham Science Publishers

Keywords: Amyloid, Alzheimer's disease, Gut microbiome, Mitochondrial abnormalities, Neuroinflammation, Neuronal dysfunction/death, Oxidative stress, Pathogenic factors, Retinopathies'.

INTRODUCTION

Ageing is the key factor of NDD, it constitutes a significant source of impairment and has contributed to a rise in interest in the immunopathological processes underlying neurodegenerative disorders. It has been revealed that ischemia, neurodegenerative diseases, immune-mediated disorders, infections, and trauma all have immunologically active central nervous systems (CNS). It frequently has the potential to harm neurons. Even though not all immune reactions in the CNS are negative, many of them promote repair and regeneration. The microglia have two distinct roles in neurodegeneration: they both harm and protect brain homeostasis. T cells, like microglia, can benefit patients improve from neurodegenerative illnesses, albeit it is unknown exactly how T cells are able to do this. Complex interactions have been revealed by thorough investigations of the neuroimmune interaction at the cellular and molecular levels, indicating that immune cells emit both neurotoxic and neuroprotective chemicals. The role of immune responses in neurodegenerative ailments is discussed, as is the hazy distinction between pathogenic and immunological responses associated with repair. To harness favorable responses for therapeutic treatments, a deeper knowledge of this dynamic will be required [1 - 3]. According to studies, the occurrence of Parkinson's disease (PD) and Alzheimer's disease (AD) has dramatically grown over the past few decades in the western world. As a result, numerous attempts at neuroprotective treatments have been undertaken or are currently being made. Ageing is accelerated by a number of co-factors, which are related to the beginning of PD and AD [4 - 6]. As an illustration, the metabolic syndrome (MetS), which can be studied further, also encompasses neurodegenerative conditions that are considered by the loss of neurons and the formation of amyloid beta. One of the key diseases in the setting of MetS is obesity, a prevalent inflammatory condition that has been demonstrated to harm the cardiovascular system and neurological system (neurodegeneration) (atherosclerosis and myocardial infarction) 2012 [7]. Traditional cytokines such as tumor necrosis factor (TNF), IL-6, interleukin (IL)-1, and monocyte chemoattractant protein-1 are released by immune cells or adipocytes in obese people [8]. In addition to boosting innate immunity and directing the adaptive immune response toward the T helper cell (h), one route of inflammation, two so-called adipokines produced by adipocytes, visfatin and leptin, assist in maintaining the inflammatory state [9]. The primary pathways are involved in the immunopathogenesis of NDD. We addressed every theory and hypothesis on the

pathophysiology of neurodegenerative illnesses that has been put out in this review.

Worldwide Data of AD

The World Health Organization estimates that 35.6 million people worldwide suffer from Alzheimer's disease. By 2030, data could increase to 65.6 million [10]. In India, 1.8 million people had dementia in 2005, and that number is likely to rise to 8 million in the following 30 years. Because the population in countries like the United States is getting older, the number of Alzheimer's sufferers will grow in the coming years [11]. According to an age-related factor, dementia and Alzheimer's disease affect 3% of those aged 65 and older, 17% of those aged 75 to 84, and 32% of those aged 85 and older. In the United States, AD and dementia will affect 5.8 million people by 2020. By 2025, there will be 7.1 million additional Alzheimer's patients in the US [12].

Pathophysiology of Immunopathogenic Neurodegenerative Disease Hypotheses

The majority of the newly hypothesized pathogenic pathways are based on the amyloid cascade theory and the tau hyperphosphorylation theory. Inflammation, oxidative stress, amyloid (A), Tau, cholinergic neuron damage, and other factors are all proposed for Alzheimer's disease, which can be characterized by changes in the ventricular regions of the brain (Fig. 1). Numerous efforts to develop anti-NDD and AD drugs have been made on the basis of these thoughts. Here are a few theories about how immunopathogenesis occurs.




Fig. (1). Anatomical difference between Healthy brain V/S Alzheimer's brain.

CHAPTER 4

Immunobiology and Immunotherapies in Huntington's Disease

Arttatrana Pal^{1,*}, Golden Kumari¹ and Sonu Kumar¹

¹ Department of Zoology, School of Life Sciences, Mahatma Gandhi Central University, Motihari, Bihar-845401, India

Abstract: Huntington's disease (HD) is a progressive neurodegenerative complication of the brain that causes uncontrolled choreatic movements, memory loss, abnormal motor function, emotional changes, and a decline in cognition as well as an inability to perform daily routine tasks. The development of advanced techniques, including genetics, molecular biology, and genetic engineering, is beginning to discover an anomalous role of immune modulatory molecules in HD onset and pathophysiological complications. However, the role of immunoregulatory molecules, which are the key chemical messengers that mediate intracellular communication to regulate cellular and nuclear functions in HD pathogenesis, is still being unexplored. Here we present recent immunological association studies on HD and emerging mechanisms for the immunotherapies implicated in HD pathogenesis. The implications of immunotherapies are very critical under both healthy and HD disease conditions. Recently, research work has established new functional aspects of their pathways. Moreover, we propose future directions for immune-related research in HD pathogenesis and potential therapeutic approaches for immune-related therapies.

Keywords: Combination therapy, Huntington's disease, Immunotherapy, Immunomodulatory drugs, Neurodegeneration.

INTRODUCTION

Huntington's disease (HD) is a progressive neurodegenerative complication of the central nervous system (CNS) marked with indecisive choreatic movements, behavioral and psychiatric disturbances, emotional and behavioral changes, along with the deterioration of cognition. Further, HD is an autosomal dominant inherited disease that transfers the mutated genes to offspring, and many individuals are born with the defective gene that favors HD. Unfortunately, the initial signs and symptoms of HD generally do not show up straight away. In this

* Corresponding Author Arttatrana Pal: Neurobiology Lab, Department of Zoology, School of Life Sciences, Mahatma Gandhi Central University, Motihari, Bihar-845401, India; E-mail: arttatanapal@mgcub.ac.in

connection, a line of research reports indicates that juvenile HD is enormously rare, and the majority of subjects start showing signs and symptoms of HD between the ages of 30 and 50 and gradually, the disease progresses differently depending on the pathophysiological conditions of the patient with time. Based on the disease progression rate, HD complications could eventually cause many deleterious physiological difficulties and make life worse over time. Specifically, subjects with HD suffer from weak muscles, chorea, or jerky muscular movements, difficulty swallowing, speaking abnormalities, irregular saccadic eye movements, insomnia, narcolepsy, depression, and difficulties with self-control.

Many studies have reported that HD develops from unusual gene patterns in the DNA, specifically by a genetic mutation in the cytosine-adenine-guanine (CAG) trinucleotide repeat expansion on the short arm of chromosome 4p16.3 in the huntingtin gene (HTT), that extends the polyglutamine tract at the huntingtin protein's N-terminus, encoding an elongated polyglutamine tract within the N-terminal of the huntingtin protein (Htt). Basically, the HTT gene has 10 to 35 repetitions in the DNA segment; however, in subjects with HD, it contains 36 to 120 repetitions. Further, if an individual retains between 30 and 36 repetitions of HTT, they could be asymptomatic. Since the individual has observed more than 40 HTT repetitions, it is quite likely that they will get HD [1]. More importantly, those subjects who carry the HTT gene, subsequently suffer from HD, while the gene's sequence mutates, the Htt protein misfolds, the abnormal protein aggregates in the brain tissues, and HD symptoms gradually manifest.

IMMUNE SYSTEM AND BRAIN

In the past decade, researchers have reported that the job of protecting the brain is not as simple and thought to be an immunologically restricted organ with an inability to generate humoral as well as cellular immune responses. However, it is interesting to note that the brain and immune system are tightly intertwined, and its protection measures possess gateways and gaps, and its confined borders are booming with an active resident of immune cells, known as microglia. In a normal, healthy brain, the resident macrophages in the CNS, known as microglial cells, are at a dormant stage. Activation of microglial cells increases the expression of their cell surface antigens and triggers the release of proinflammatory mediators like IL-6, IL-12, and TNF- α [2]. A crucial aspect of secretions of these proinflammatory mediators causes interaction between the nearby microglial cells, astrocyte cells, T cells, neuron cells, and myeloid progenitor cells [3].

Immune System and HD brain

The immune response in brain tissues can be triggered by the existence of any pathological lesion within the brain caused by either internal or external factors. Abnormal immune responses to the aberrant protein folding as well as aggregates in neuronal compartments promote neuroinflammation, and are present in the majority of neurodegenerative disorders, including HD, and lead to neuronal degeneration. Moreover, the mHtt clumps are observed in HD subjects, which are coherent with some other neurodegenerative disorders. Neostriatal atrophy is a prominent characteristic in HD brains that indicates severe neurodegeneration in the neostriatum, notably in the putamen and caudate. However, protein aggregation in the brain tissues triggers apoptosis, which damages neurons, and subsequently, the production of apoptotic bodies can trigger microglia activation in the CNS innate immune system. The fact that the carriers of the gene do not show the typical signs and symptoms of typical HD subjects offers vital hints to the evolution and consequences of HD in this correlation, where the progression of HD is yet unknown. These facts, however, also reveal that mHtt protein aggregation provokes activated microglia to accumulate in the striatum, leading to early neuronal dysfunction, significantly increasing pathogenic extra synaptic N-methyl-D-aspartate receptor (NMDAR) signalling, decreased synaptic connectivity, and a loss of brain-derived neurotrophic factor [4].

Mechanisms of Neurodegeneration in HD

Over the past two decades, several *in vitro*, *in vivo*, and postmortem studies have been carried out to comprehend the processes by which the mHTT gene exerts its adverse effects on HD subject's brain tissue. The deleterious pathological processes in the HD brain include but are not restricted to, NMDAR-mediated excitotoxicity, dopaminergic-based dysfunction, mitochondrial dysfunction, oxidative-nitrosative stress, dysregulated autophagy, abnormal protein aggregates, disruption of gene transcription, and also the loss of trophic support. Recent advances in genetic, biochemical, molecular, histopathological, and mechanistic evidence showed immune pathway dysregulation in HD pathogenesis, with alterations in cytokine signalling, immune cell proliferation/migration, changed phagocytosis, and reactive gliosis as common characteristics of HD. Moreover, studies have reported that the pathological signature of HD proteinopathies is chronic immune activation, encompassing innate and adaptive immune responses Fig. (1) [5]. Over the past decade, studies have reported a significant connection between pathogenic misfolded protein aggregation and immune activation in the HD brain. Peripheral immune cells as well as brain-resident cells both have high levels of mHTT gene expression, which caused inflammatory mediators' stimulation for these cells [6]. The secretion of proinflammatory cytokines,

Introduction to Gut Microbiota and their Effects on Various Brain Disorders

Afreen Usmani^{1,*} and Anuradha Mishra²

¹ Department of Pharmacology, MESCO Institute of Pharmacy, Amroha 244221, India

² Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida, 201313 (U.P.) India

Abstract: Human gut microbiota (GM) research has emerged as one of the most promising fields in recent years. Moreover, a major area of interest is the connection between GM and several human disorders. Numerous recent studies have demonstrated the vital roles that the gut microbiome plays in human physiology and pathology. Additionally, microbiome-based medicines have been used to cure illnesses. In biomedical research, aging and neurodegenerative conditions such as Alzheimer's and Parkinson's disease have also attracted a lot of attention. To explore the potential pathogenic or therapeutic impacts of GM in diseases, several researchers have examined the connections between these factors. Numerous biologically active chemicals produced by microbiota have an impact on neurochemistry *via* neuroendocrine, immunological, and metabolic pathways. Gastrointestinal functional disturbances can manifest well in advance of the onset of neurodegenerative disorders. Furthermore, recent advancements in both preclinical and clinical research have indicated that the composition of the GM assumes a significant role in governing the dynamic interplay between the gut-brain axis, potentially bearing relevance to the etiology of neurodegenerative maladies. This chapter focuses on the relationship between the microbiota and neurodegeneration, as well as the pertinent mechanisms, present applications, and potential future prospects for microbiome-based therapy.

Keywords: Amyotrophic Lateral Sclerosis, Alzheimer's, Huntington's Disease, Intestinal Microbiome, Microbiota, Neurodegeneration, Parkinson's.

INTRODUCTION

The word “microbiota” refers to the symbiotic bacteria, archaea, fungi, protozoa, and viruses that coexist with humans and populate their bodies. These structured communities of microbes live in our digestive, respiratory, urogenital, skin, and oral systems. The GM contains roughly 1000 different species of bacteria, 99% of

* Corresponding author Afreen Usmani: Department of Pharmacology, MESCO Institute of Pharmacy, Amroha 244221, India; E-mail: afreenusmaniu@gmail.com

which are exclusively anaerobic. It is the most densely populated microbiome. A wide range of metabolic processes and activities, including antimicrobial defense, immunomodulation, control of the host epigenetic machinery, and food and drug metabolism, are covered by integrated microbiome products [1, 2]. The GM might be thought of as an additional organ as a result of all these abilities. There are hundreds of commensal species in the oral cavity, the majority of which are facultative anaerobes or aerobes. This makes the oral cavity's microbiota the second most diverse microbial community in the body which plays a significant role in shielding the body from the spread of microorganisms that cause illness [3]. In the realm of scientific inquiry, several factors, such as the administration of drugs like antibiotics, dietary patterns, living conditions, and chronological age, stand out as noteworthy variables capable of exerting influence over the equilibrium of the microbiota. Initially considered devoid of microbial presence at birth, the human gastrointestinal tract and oral cavity rapidly undergo colonization by bacteria, culminating in the attainment of an “adult-like” microbial composition at approximately one year of age. Subsequently, throughout the period of adulthood, both microbiotas demonstrate a relatively stable configuration. Nevertheless, advancing age introduces discernible alterations in these microbial communities, manifesting as an augmented prevalence of *Lactobacilli*, *Staphylococci*, and yeasts within the oral cavity, whereas a reduced prevalence of *Firmicutes*, *Bifidobacteria*, and *Bacteroidetes* within the gut [4, 5].

The microbiome affects the brain through various pathways. The gut-brain axis, which largely consists of neuroendocrine, neuronal, endocrine, and immunological signaling pathways, is a two-way functional communication network between the brain and the intestine. Through these routes, the metabolites of the GM, including short-chain fatty acids, gamma-aminobutyric acid (GABA), serotonin, kynurenines, norepinephrine, and histamine, among others, control a number of cerebral physiological functions. In response to signals from the dysbiosis of the intestinal microbiome, the brain experiences low-grade inflammation, increased oxidative stress, disturbed energy metabolism, and accelerated cellular senescence, which all contribute to the degenerative processes of neurodegeneration as shown in Fig. (1) [6 - 8]. The vagus nerve, which connects the central nervous system (CNS) and the enteric nervous system directly, is an example of a well-studied method [9]. Additionally, bacteria affect the immune system's growth and control, which may change how the immune and CNS systems interact. Additionally, bacteria release metabolites and neuroactive chemicals that could travel through the bloodstream to the brain. Short-chain fatty acids, such as butyrate, which are fermentation products obtained from the diet and important for microglia homeostasis, serve as an illustration of this. Furthermore, the microbiota produces and secretes substances (such as neurotoxins, neurotransmitters, lipopolysaccharides, and amyloids) that can harm

the CNS's neurochemistry, causing amyloidosis, synucleinopathies, and tauopathies, which in turn aid in the onset and/or progression of neurodegenerative diseases [10]. The quality of life of patients with neurodegenerative disorders can be significantly improved by early diagnosis, monitoring, and treatment of unpleasant gastrointestinal symptoms, including normalization of the microbiota [11, 12].




Fig. (1). Role of microbiota in pathogenesis of neurodegeneration.

Currently, research is being conducted on the use of probiotics and dietary supplements for the prevention and potential therapy of CNS diseases that can restore normal neuroendocrine, neuroimmune, and humoral systems [13]. The impact of probiotic microorganisms is extremely varied and can take the form of any or all of the following: probiotics positively modulate immunity to infectious diseases; they are involved in the synthesis of several essential vitamins, particularly vitamins B and K; synthesize significant metabolites for the host

Interplay Between Gut-microbiota and Neurodegeneration

Sumel Ashique^{1,*}, Radheshyam Pal¹, Shubneesh Kumar², Bharti Verma³, Nitish Kumar³, Ivan Kahwa⁴, Arshad Farid⁵, Neeraj Mishra^{6,*}, Prashant Kumar⁷ and Farzad Taghizadeh-Hesary^{8,9}

¹ Department of Pharmaceutics, Pandaveswar School of Pharmacy, Pandaveswar, West Bengal-713346, India

² Department of Pharmaceutics, Bharat Institute of Technology, School of Pharmacy, Meerut-UP-250103, India

³ SRM Modinagar College of Pharmacy, SRM Institute of Science and Technology (Deemed to be University), Delhi-NCR Campus, Modinagar, Ghaziabad, Uttar Pradesh-201204, India

⁴ Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda

⁵ Gomal Center of Biochemistry and Biotechnology, Gomal University, D.I.Khan, KPK, Pakistan

⁶ Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Madhya Pradesh (AUMP), Gwalior, MP-474005, India

⁷ Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, Uttar Pradesh, India

⁸ Assistant Professor, ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

⁹ Clinical Oncology Department, Iran University of Medical Sciences, Tehran, Iran


Abstract: Introduction: The body of scientific evidence linking the microbiome to many diseases has grown dramatically over the past several years; neurological diseases have also shown a similar tendency. As a result, the gut-brain axis theory as well as the notion that there could be a connection between the gut microbiome and several CNS-related disorders whose pathophysiology is still not known have both emerged.

Development: We look at the role played by gut microbiomes in the gut-brain axis as well as the neurological conditions neuromyelitis optica, Alzheimer's, amyotrophic lateral sclerosis, Parkinson's, and multiple sclerosis, where changes in the gut microbiota have been linked to human studies.

* **Corresponding authors Sumel Ashique and Neeraj Mishra:** Department of Pharmaceutics, Pandaveswar School of Pharmacy, Pandaveswar, West Bengal- 713346, India; and Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Madhya Pradesh (AUMP), Gwalior, MP-474005, India; E-mails: ashiquesumel007@gmail.com, neerajdops@gmail.com

Anuradha Mishra, Preeti Bajpai, and Tarique Mahmood Ansari (Eds.)
All rights reserved-© 2024 Bentham Science Publishers

Conclusions: The amount of data connecting gut microbiota to different neurological illnesses has significantly increased. Today, there is no longer any doubt that the gut microbiota of the host influences brain function. This review assembles a sizable body of credible research that is essential in emphasizing the crucial role of microbiota colonization in neurodevelopment and how changes in microbiota dynamics might have an age-dependent effect on brain function.



Keywords: Gut microbiota, Neurodegenerative disorders, Oxidative stress.

INTRODUCTION

The gut-brain axis (GBA) is an extensive network of interactions between the brain and the gut microbiome. The maintenance of the body's overall homeostasis depends on the GBA, which includes multiple biological systems [1]. Signals are sent from the stomach to the central nervous system (CNS) and vice versa *via* either direct channels involving the autonomic nervous system or indirect pathways utilizing metabolites and chemical transmitters [2]. The makeup of the gut microbiota can affect each of these interactions, which can change. In recent times, the GBA has gathered attention because of its newly discovered potential in regulating health and related diseases as well as its key potential value as a therapeutic target. The gut microbiota has an impact on a variety of elements of brain function and development, including permeability, myelination, neurogenesis, and blood-brain barrier (BBB) formation [3 - 5]. The pathogenesis of several brain disorders, including neurodegenerative diseases (ND), may involve GBA disruption [6, 7]. The possibility that the gut microbiota has a role in the progression of inflammation and degeneration in the central nervous system, but still the subject of much discussion. In this review, a summary of the available research on the function that the gut microbiota plays in neurodegenerative

diseases is provided, with a particular focus on the current and prospective GBA-targeting therapy approaches. However, with the increase in people's age, the prevalence of NDs rises, placing a heavier cost on society [8, 9]. Unfortunately, despite numerous current clinical trials, there is no effective treatment for these disorders due to their uncertain origin and the intricacy of the nervous system. The gut contains a variety of microbes known as the gut microbiota, which are found in numerous ecological niches and include archaea, viruses, bacteria, and different eukaryotic species including fungi and protozoa [10]. Numerous aspects of the host's physiology, such as nutrient metabolism, infection prevention, the immune system, and neuron growth are significantly affected by the gut microbiome [11]. The gut microbiota is adapting to a new environment as a result of industrial growth, urbanization, and advancements in food and medical technologies [12]. Given that it plays a crucial role in NDs and in regulating the central nervous system's tissue-resident immune cells' development, proliferation, maturation, and activation, the significance of gut microbiota has recently come to light [13]. Through the use of neurotransmitters and other metabolites, the gut-brain axis contributes to the bidirectional [14, 15] link between the gut microbiome and the brain [16, 17]. We list the potential pathogenic functions of the microbiota in NDs in this review.

GUT MICROBIOTA

The host and the diverse, dynamic bacteria that make up the gut microbiota form a symbiotic connection. The metabolic interactions and activities of the gut microbiomes affect normal physiology and the host's susceptibility to diseases [18]. Individual differences and diversity at the bacterial strain level are caused by variations in gut pH, immunological factors, and digesting enzymes [19]. Additionally, each person is home to a unique microbial community that contributes to the establishment of a durable and stable condition. In the mucosa of an adult gut, Bacteroidetes and Firmicutes prevail in terms of number over Actinobacteria, Proteobacteria, and Verrucomicrobia [20, 21]. By secreting microbial substances including lipids, vitamins, and vital amino acids, the gut microbiota has the potential to have a direct impact on human health [22]. These variables may influence the gut-microbiota *via* neuronal, endocrine, and immunological signaling pathways, which may then affect physiological processes such as the development of the neurological system as we age and the function of the GIT (gastrointestinal tract) [23, 24].

Gut Microbiota and Neurodegenerative Disease: A Correlation

The gut microbiome is thought to be crucial for controlling human behavior, myelination, neurogenesis, and activation of microglial cells in the brain, as well

Epigenetic Regulation of Microglia: Plausible Mechanism and Interventional Approaches in Neurodegeneration

Sameen Shafi¹, Hafizur Rahman Khan² and Preeti Bajpai^{1,*}

¹ Department of Zoology, Mahatma Gandhi Central University, Motihari-845401, Bihar, India

² Department of Zoology, Maharani Janki Kunwar College, Bettiah-845438, Bihar, India

Abstract: Microglia, the brain resident macrophages perform a wide range of functions ranging from brain development, equilibrium, maintenance in the brain microenvironment, injury repair and the preservation of neuronal networks. Cellular elasticity is a prerequisite for the multi-dimensional tasks performed by microglia. Epigenetic modulations are critically involved in altering gene expression finely coordinating with the phenotypic plasticity in microglia. Any change in its tuning favors the inflammatory state of the brain, which leads to detrimental effects on the nervous system. The present review offers an insightful exploration into the origin of microglia, shedding light on its vital functions and the intricate mechanisms that govern the epigenetic modification of microglia in neurodegenerative disorders. Furthermore, it explores potential avenues for mitigating these diseases.

Keywords: Histone acetylation, Histone methylation, Microglia, Neurodegenerative disorders.

INTRODUCTION

Neuroinflammation stands as a central feature in the landscape of neurodegenerative diseases, with its roots traced back to a cast of inflammatory actors including cytokines, chemokines, reactive oxygen species, and other messengers of inflammation. This ensemble of troublemakers is predominantly dispatched into action by the brain's immune sentinels, microglial cells, and astrocytes. When these resident cells engage with pro-inflammatory agents and cytokines like TNF- α , IFN γ , IL1, and IL-6, a symphony of responses is set in motion [1].

* Corresponding author Preeti Bajpai: Department of Zoology, Mahatma Gandhi Central University, Motihari-845401, Bihar, India; E-mail: preetibajpai@mgcub.ac.in

Microglial cells, armed with Pattern Recognition Receptors, form ligand-receptor complexes that trigger a cascade of signals, ultimately leading to the production of neurotoxic substances that pave the way for neurodegenerative disorders. The relentless bombardment of these stimuli instigates both physical and functional transformations in microglia, further fuelling the flames of neurodegeneration. These microglial cells, functioning as the brain's resident macrophages, possess a repertoire of genes responsible for maintaining the brain's well-being and safeguarding against threats. Any external stimulus that disrupts their housekeeping and protective functions throws them into disarray, setting the stage for neuroinflammation. Fortunately, immune checkpoints like Trem2, chemokine CX3CR1, and the progranulin pathways regulate this neuroinflammation and manage scavenger receptor pathways. However, interference with these regulatory mechanisms can tip the balance, resulting in microglial dysfunction and neuronal harm [2].

The cascade of these events eventually leads to the progression of debilitating diseases such as Parkinson's disease, presenile dementia, prion disease, amyotrophic lateral sclerosis, dementia, autism spectrum disorder, Huntington's disease, and chronic traumatic encephalopathy. Consequently, curbing inflammatory responses by maintaining regulatory control over microglial activation or inducing a switch in their phenotype emerges as a promising avenue for identifying therapeutic targets and designing interventions against neurodegenerative diseases.

Furthermore, the interplay between epigenetic alterations and a broad spectrum of ailments, including neurodegenerative disorders, cancers, and autoimmune conditions, has been extensively documented. Research spanning the past two decades has shed light on the critical role of epigenetic modifications in shaping the physiological and phenotypic behaviours of microglia. This knowledge underscores the potential for manipulating epigenetic changes to develop effective preventive and therapeutic approaches against these diseases. Consequently, this chapter aims to delve into the origin and functions of microglia while unravelling the intricate mechanisms behind epigenetic modifications, offering valuable insights for future research and therapeutic interventions.

Origin of Microglia

Microglial cells, approximately 10-15% of the cells in the central nervous system (CNS), play a crucial role as mononuclear phagocytic cells [3]. They contribute to neuronal circuits during development and a state of equilibrium in the brain. Recent fate-mapping studies have illuminated the origin of microglia, suggesting

that they originate from progenitor cells possessing erythromyeloid characteristics within the yolk sac. These cells then migrate to the brain around embryonic days 9.5 to 10.5 [4]. Despite these insights, the exact origin of microglia continues to be a subject of exploration. Pioneering research conducted by Cuadros *et al.* in 1993, which involved experiments on chick embryos, initially proposed that microglial cells derive from the embryonic yolk sac [5]. In a quest to examine the necessity of a blood supply for the infiltration of primordial myeloid cells during development, a research group conducted experiments involving the fusion of chick embryos with quail yolk sacs. Remarkably, their findings provided evidence suggesting that blood supply may not be indispensable for the invasion of these cells. Furthermore, in 1999, Alliot *et al.* bolstered this hypothesis by demonstrating the presence of microglia precursors in the yolk sac [6]. Nevertheless, while these discoveries yielded valuable insights into the temporal and spatial distribution of microglia cells during embryonic development, they fell short of definitively resolving the issue of microglial origin.

Moreover, some researchers have suggested that the precursors of microglia originate from the neuroectoderm and/or mesoderm present in the developing brain [7]. The majority (approximately 95%) of microglial cell formation occurs after the development of the blood-brain barrier. The microglial population in the brain is maintained through the local proliferation of progenitor cells. Another hypothesis proposes that bone marrow stem cells (BMSC) present in the bloodstream infiltrate the brain and differentiate into microglial cells [7]. Additionally, a different group of researchers have observed that during injury, monocyte cells of bone marrow origin are predominantly found in the brain [8].

Definitive evidence regarding the origin of microglia from the embryonic yolk sac has been established through the research conducted by Ganzhou *et al.* [9]. They employed a meticulous approach, crossing ROSA26 floxed reporter mice with tamoxifen-inducible Cre recombinase-expressing mice under the control of the yolk sac-specific Runx1 promoter (Runt-related transcription factor 1).

Activating the Runx1-driven Cre recombinase at various stages of embryonic development through tamoxifen induction led the researchers to trace the fate of cells derived from the yolk sac. The findings conclusively demonstrated that microglial progenitor cells originate from the yolk sac and subsequently migrate into the brain through the bloodstream.

A separate study conducted by Schulz *et al.* in 2012, provided further affirmation of microglial derivation from the yolk sac. The research group reported that the transcription factor MYB which plays a key role in haematopoiesis, is not essen-

Epigenetics as Diagnostic and Therapeutic Tool in Neurodegenerative Disorders

Rufaida Wasim^{1,*}, Tarique Mahmood¹, Farogh Ahsan¹, Aditya Singh¹ and Asad Ahmad¹

¹ Department of Pharmacy, Integral University, Lucknow, India-226026

Abstract: Epigenetics is a field that is concerned with the investigation of heritable modifications in gene expression that transpire without DNA sequence alterations, thereby establishing a connection between the genome and its surroundings. Epigenetics simply analyzes gene expression amendment beyond variation to the DNA sequence. The gradual accumulation of epigenetic changes over the course of an individual's life span may contribute to neurodegeneration. This chapter deals with epigenetic alteration, which affects the progress of neurodegeneration with age. Epigenetic regulation, encompassing DNA methylation and histone modification, has been implicated in the anomalous alterations in gene expression that occur during the progression of neurodegeneration. The concept of epigenetics is useful to synthesize novel medications to target these disorders. In recent times, a plethora of epigenetics-based medications have been developed for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. Due to a major lack of early screening processes that allow therapeutic agents to be distributed to afflicted neurons paramount to cell death, many neurological conditions have severely restricted options for treatment. Significant progress has been seen in neurodegenerative disease biomarkers. These biomarkers have been unfortunate, due to substantial disparities amidst the tissues acclimated to source biomarkers and biomarkers of disease. Neurodegeneration may be exacerbated by epigenetic changes that develop gradually. Epigenetic biomarkers could aid in the diagnosis, and monitoring, of neurodegenerative diseases.

Keywords: Diagnosis, Epigenetics, Neurodegenerative disorders, Treatment.

INTRODUCTION

Neurodegenerative disorders pose an enormous challenge and represent some of the most severe health problems that societies will face around the world. These are progressive and incurable conditions, which arise from the continuous degene-

* Corresponding author Rufaida Wasim: Department of Pharmacy, Integral University, Lucknow, India;
E-mail: rufaidawasim08@gmail.com

ration and death of nerve cells. A majority of these disorders become more prevalent with age, such as Alzheimer's and Parkinson's disease. The burden of these diseases is increasing at an alarming, with incalculable costs both in terms of human and economic resources. According to a comprehensive study by the World Health Organization, the World Bank, and the Harvard School of Public Health (the Global Burden of Disease Study), neurodegenerative diseases such as dementia rank eighth in terms of disease burden in developed regions in 2030. Neurodegenerative diseases are anticipated to become the second most prevalent cause of mortality across the globe by the year 2030, surpassing cancer. It is important to emphasize that these predictions are not definite, however, the amalgamation of these projections with the present situation undeniably confirms that the public apprehension regarding neurodegenerative disorders is escalating [1].

Neurodegenerative disorders have both genetic and environmental factors. The largest proportion arises due to the complex interplay between these factors. As a result, it is difficult to delineate specific risk factors, useful biomarkers, potential new therapeutic targets and agents, and even a definite diagnosis. The pathological characteristics of the brain during the process of neurodegeneration exhibit significant overlap among different types of neurodegenerative cognitive and motor impairment, adding to the complexity of diagnosis and treatment. The correlation between pathological findings and clinical findings is not always straightforward. Extensive neuropathology does not necessarily indicate severely impaired neurological function, nor does minor pathology necessarily mean only mild neurological function impairment. The reason for this is that neuropathological processes may not be the cause of the underlying disease at early stages, but may simply be a reflection of fundamental disease processes that are yet to be understood in most neurodegenerative disorders. However, as the disease progresses, neuropathological changes are likely to contribute to disease progression in a positive feedback loop [2].

Currently, a clear diagnostic test that can identify the presence, or absence of a neurodegenerative disease does not exist. The diagnosis of an individual is dependent on the clinical evaluation of their symptoms and specific neuroimaging characteristics, a process that can take numerous years to complete. However, there are certain exceptions to this, such as monogenic diseases like Huntington's disease (HD), where the diagnosis can be confirmed through a specific genetic test. Thus, the development of an accurate diagnostic test for neurodegenerative diseases is a pressing need in the field of medicine.

Neurodegenerative diseases have complex underlying mechanisms that are not yet fully understood. A significant number of these diseases are characterized by the

aggregation of intracellular proteins, but it is unknown whether this is a primary mechanism or a consequence of another disturbed cell function. The potential mechanisms of neurodegeneration are numerous and varied, including primary effects of protein homeostasis, disrupted protein degradation, gene expression, transcriptional regulation, and mitochondrial dysfunction. Consequently, there is an urgent need to further explore the pathophysiology of these diseases to improve early diagnosis and develop disease-modifying treatments that can reduce their impact on patients' lives [2].

EARLY DIAGNOSIS AND TREATMENT

The schedule of administering drugs governs the therapeutic effectiveness in neurodegenerative diseases. Folate optimizes cognitive problems in people with moderate Alzheimer's disease [3], but not in people with severe Alzheimer's disease [4]. Recognizing the importance of prompt medical approaches, early diagnosis of neurodegenerative diseases could significantly improve drug efficacy. Thus, early symptoms of neurodegenerative disorders, nascent disease-associated neural features, are therefore examined with great attention [5].

Neurons in early-stage Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and dendrite anomalies triggered by the disease can be linked to structural changes in the dendritic cytoskeleton [6, 7]. Impeded axonal transport has been seen in Alzheimer's disease in fruit flies [8], mice [9, 10], fruit fly model [11, 12], and squid [13].

A significant proportion of neurological diseases are linked to mitochondrial dysfunctions such as respiratory, trafficking, inter-organelle communication, and quality control issues [14]. A broad range of anomalous neural features observed in neurodegenerative disorders imply that unusual changes in cell functions eventuate all through the framework [15]. More pertinently, even though they appear early, these system-wide atypical alterations have the potential to be utilized as initial neurodegenerative disease markers.

NEURODEGENERATIVE DISORDERS AND EPIGENETIC ALTERATION

One probable explanation for such change is epigenetic alteration. Epigenetic modification, characterised by modifications in the gene expression that eventuate unvarying changes in the intrinsic nucleotide sequence [16], has been linked to neurodegenerative disorders. Drugs that reinstate neuropathological disease-associated epigenetic modifications have been evinced in Alzheimer's disease (AD) [17], Parkinson's disease (PD) [18], and Huntington's disease (HD) models to reduce disease toxicity [19, 20]. Recently, significant efforts have been made

CHAPTER 9

Current Therapeutic Options and Repurposed Drugs for Neurodegeneration

Suneela Dhaneshwar^{1,*}, Mohammad Aadil Bhat², Anuradha Singh² and Supriya Roy²

¹ Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-410206, Maharashtra, India

² Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.

Abstract: Neurodegenerative diseases are a vast collection of neurological disorders with various clinical and pathological manifestations that impact particular subsets of neurons in distinct functional anatomic systems; they begin for unexplained reasons and advance inexorably. Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Huntington's disease, Friedreich ataxia, and Spinal muscular atrophy are the major neurodegenerative diseases. The prevalence and incidence of these diseases rise dramatically with age; thus, the number of cases is expected to increase for the foreseeable future as life spans in many countries continue to increase. Although there are several medicines currently approved for managing neurodegenerative disorders, a large majority of them only help with associated symptoms. The limitations of pharmacotherapy in these disorders have led to an urgent shift towards the development of novel compounds, interventions, and methods that target shared features across the spectrum of neurodegenerative diseases. Drug repurposing is a novel strategy where existing drugs that have already been approved as safe in patients for the management of certain diseases are redeployed to treat other, unindicated diseases. In this chapter, we have covered the current therapeutic options and drugs that can be repurposed or have the potential to be repurposed for the management of various neurodegenerative diseases.

Keywords: Amyotrophic lateral sclerosis, Friedreich ataxia, Huntington's disease, Spinal muscular atrophy.

INTRODUCTION

Neurodegenerative disease is a ubiquitous term encompassing a variety of conditions causing impairment and death of the neurons. These conditions are

* **Corresponding author Suneela Dhaneshwar:** Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-410206, Maharashtra, India; E-mail: suneeladhaneshwar@rediffmail.com

frequently persistent, and deadly and impact basic functionalities. Protein aggregation, a high load of reactive oxygen species, the subsequent accumulation of inflammatory processes and oxidative stress in the central nervous system (CNS), abnormal ubiquitination, neurotransmitter depletion, or insufficient biosynthesis are all important precipitating factors in neurodegenerative diseases. Whilst humungous research is aimed at finding the cure for these neurodegenerative diseases, there is a huge gap between the understanding of underlying molecular pathways involved in their pathophysiology and actual targets available for developing potential drug candidates against them. Pre-clinical and clinical studies of novel drugs for neurodegenerative diseases face major challenges such as inadequate disease characterization, unavailability of appropriate translational animal models, and reliable biological markers that could help in the realistic prediction of disease progression rate in single patients. Alzheimer's disease (AD), Parkinson's disease (PD), Friedreich ataxia (FA), Spinal muscular atrophy (SMA), Huntington's disease (HD), and Amyotrophic lateral sclerosis (ALS) are some of those neurodegenerative disorders that still await the safer and effective therapies that will aim at removing the underlying cause and not just symptomatic relief with minimal adverse effects.

Drug Repurposing

The discovery of new drug molecules is time-consuming and costly with very low success rates. Drug repositioning which means finding new uses for known drugs, is one of the modern and most cost-effective approaches to drug development, with a history of current drug use [1]. Based on the data about the quantity and quality of the biological, pharmacological, toxicological, physicochemical, and pharmacokinetic properties of drug particles, the strategies employed in drug repurposing can be classified into three categories: target-oriented, drug-oriented, target-oriented, and disease/therapy-oriented [2]. Drug repositioning can be observed as a response to the elusive output of neurodegeneration drug discovery, as an arrangement to reduce the time development, and affordable therapy to gain the improved request and unfilled requisite of individuals suffering from neurodegeneration.

The preference and the main driver for the potential interest in drug repurposing over conventional drug discovery is a smaller number of new chemical entities that clear all phases of clinical trials, a huge number of unaddressed diseases, very high costs, and extended timelines involved in the research and development, increase in the regulatory demands, expiry of patents, and mounting competition of branded medicines with generics. Given this challenging scenario, drug repurposing is considered a propitious option to address these unmet needs. Over the last few decades, drug repurposing has evolved as a master plan to search for

newer uses for existing drugs not only by serendipity but by using more advanced and intricate computational tools. On-target and off-target approaches are mainly used in the pursuit of repositioning drugs.

ALZHEIMER'S DISEASE (AD)

AD is the leading prevalent factor of dementia among old age people. It is an age-related, incurable neurodegenerative, and progressive condition characterized by memory and cognitive deterioration [3]. The disorder frequently begins with the short-term loss of memory and continues to include language impairments, confusion, changes in mood, and behavioral concerns (sleep changes, agitation, psychosis). The disorder eventually leads to loss of physiological functions and, lastly, death [4]. Based on the core pathophysiology of AD, current research suggests that the primary histological lesions of AD are intra-cellular Tau neurofibrillary tangles and extracellular amyloid plaques. According to the "amyloid hypothesis," the brain's generation of amyloid-beta ($A\beta$) initiates a chain reaction that results in the clinical presentation of AD. The amyloid cascade, which causes neurotoxicity, is triggered by the production of amyloid oligomers [5]. There are presently no approved medicines that tackle the pathophysiology of AD directly. Existing therapies are symptomatic, aiming to improve cognitive function through two distinct mechanisms: agonism and antagonism of the cholinergic system and N-methyl-D-aspartate receptor (NMDA-receptor) [4].

There is a clear need for new drugs or therapies since the benefits provided by current treatments for AD are optimum (Fig. 1). The current treatments for AD are only symptomatic which suffer from many limitations. The present treatments display dose-related side effects like diarrhea, vomiting, abdominal cramps, bradycardia, nausea, and higher syncope rates [6]. Disease management is expensive in low-income countries. Another challenge is getting the drug over the blood-brain barrier, which is now the only available treatment option [7]. Confusion, dizziness, and headache were the supreme adverse events in memantine trials [8].

This figure provides an overview of the multifaceted landscape of current drug treatments for AD. From acetylcholinesterase (AChE) inhibitors to NMDA receptor modulators and emerging experimental therapies. These approaches aimed at managing the complex symptoms and underlying pathology of AD, offering hope for improved cognitive function and quality of life for affected individuals.

SUBJECT INDEX**A**

- Abdominal cramps 179
 Abnormal 32, 67
 immune responses 67
 protein dynamics 32
 Abnormalities 11, 33, 43, 52, 54, 81, 181, 198, 199
 behavioral 54
 mitochondrial 11, 33
 motor neuron 198
 neuronal degenerative 52
 Acid(s) 9, 25, 38, 54, 112, 123, 124, 194, 196
 ascorbic 25
 ferulic 9, 123, 124
 fumaric 196
 glutamic 54
 isobutyric 112
 malonic 194
 nucleic 38
 phenolic 123
 propionic 112, 123
 Action 18, 73, 185
 neuroprotective 18, 185
 phagocytic 73
 Activation 25, 38, 156, 190
 dysregulated pro-inflammatory 25
 mitophagy 190
 synaptic NMDA 38
 transcriptional 156
 Activities 93, 155, 186, 187, 199
 anti-amyloid 186
 anti-inflammatory 93
 cognitive 186, 187
 ligase 155
 neuroinflammatory 199
 Acute promyelocytic leukaemia (APL) 183
 Adaptive immune 33, 48, 67, 69, 71, 72, 77, 93
 based response 72
 responses 33, 48, 67, 69, 71, 72, 77, 93
 Adaptive response 79
 Age, chronological 89
 Age-related 111, 125
 dementia 111
 neurodegeneration 125
 Agents 84, 146, 162, 163, 167
 pro-inflammatory 146
 therapeutic 162
 Aggregates 8, 37, 42, 46, 66, 67
 abnormal protein 66, 67
 cytoplasmic protein 46
 Agitation, mitigating 170
 Alzheimer's 4, 10, 41, 182, 184
 brains 41, 182, 184
 disorders 4, 10
 Alzheimer's disease 164
 early-stage 164
 moderate 164
 AMP-activated protein 185
 AMPA glutamate receptors 152
 Amyloid 3, 35, 36, 37, 41, 185, 187
 beta peptides 36
 deposition 3
 precursor protein (APP) 35, 36, 37, 41, 185, 187
 Amyloidogenesis 19
 Amyloidosis 7, 90, 93, 111
 Amyotrophic lateral sclerosis 4, 88, 95, 200
 Angiogenesis damage 56
 Angiotensin-converting enzyme (ACE) 186
 Anti-astrogliosis effects 180
 Anti-cancer agents 180
 Anti-inflammatory 24, 121, 156
 drugs 24
 effects 121, 156
 Antioxidant-responsive elements 195
 Apoptosis 3, 9, 20, 21, 38, 43, 44, 45, 46, 47, 52
 Argyrophilic grain disease (AGD) 40
 Astrogliopathy 23
 Astrogliosis 23, 68
 Atherosclerosis 33, 44
 Autism spectrum disorder (ASD) 118, 147

Subject Index

Autoimmune disorders 53, 155
Autonomic dysfunctions 7
Autophagy 3, 43, 44, 47, 51, 67, 121, 182
 deregulation 43
 dysregulated 67

B

Bradycardia 179
Bradykinesia 112, 188
Brain 91, 184, 203
 neuroplasticity 91
 tissue autopsy 203
 tumors 184

C

Cancer, lung 183
Chemicals 33, 89, 110, 122
 neuroactive 89, 110, 122
 neuroprotective 33
Chronic 40, 147, 203
 obstructive pulmonary disease (COPD) 203
 traumatic encephalopathies (CTE) 40, 147
CNS 49, 75, 90, 108, 119
 diseases 49, 90
 disorders and cerebrovascular inflammation 108
 infiltrating macrophages 75
 neurotransmitters 119
Cognitive dysfunction 112
Constipation 95
CREB binding protein (CBP) 168

D

Damage 5, 10, 11, 17, 22, 37, 44, 45, 92, 94, 120, 124, 125, 183, 197
 genetic 92
 neural 125
 nucleic acid 45
 oxidative 10, 11, 120, 124, 197
Degeneration, neuronal 40, 47, 49, 67, 199
Degenerative brain diseases 4
Diarrhea 54, 179
Disease(s) 2, 3, 4, 5, 6, 11, 22, 25, 26, 40, 41, 45, 51, 56, 73, 92, 106, 119, 147, 162, 163, 164, 172, 177, 183, 185, 203
 autoimmune 51

Advances in Diagnostics and Immunotherapeutics 221

 biomarkers, neurodegenerative 162
 cerebrovascular 56, 185
 degenerative 6
 inflammatory bowel 119
 motor neuron 4, 11, 203
 neurodegeneration Huntington's 73
 pathogenesis 22
 progression, neurodegenerative 25
 skin 183
Disorders 2, 3, 5, 7, 9, 17, 33, 37, 38, 41, 43, 70, 118, 147, 162, 163, 177, 179
 autism spectrum 118, 147
 cerebrovascular 70
 immune-mediated 33
 lysosomal storage 43
Dysautonomia 112
Dysbiosis 52, 53, 89, 110
Dysfunction, neurotrophic 47
Dyskinesia 194
Dysregulation 46, 67, 91, 114
 immune pathway 67
 immunological 114

E

Enzymes 10, 22, 37, 114, 153, 156, 167, 186
 angiotensin-converting 186
 cyclooxygenase 22
 demethylase 156
Epidermal growth factor receptor inhibitors (EGFRI) 180
Epilepsy 10, 45, 152, 187

F

Factors 1, 2, 3, 6, 19, 21, 22, 33, 34, 38, 43, 50, 76, 84, 88, 89, 106, 121, 149, 150, 152, 182
 angiogenic 150
 blocking vascular endothelial growth 182
 fibroblast growth 121
 immunological 106
 inflammatory 19, 22
 transcriptional 19
 tumor necrosis 21, 33, 76
 vascular endothelial growth 150
Fast axonal transport (FAT) 46
Fecal microbiota transplantation (FMT) 93, 98, 112

Fermentation 91, 122
 anaerobic 122
Ferroptosis 38
Frataxin silencing 196
Functions 21, 50, 81, 119, 154, 166
 homeostatic 21
 immunological 119
 immunoregulatory 81
 neuronal 166
 neuroprotective 50
 targeting microglial 154

G

Gas chromatography-mass spectrometry 117
Gastrointestinal 88, 106, 110, 115
 systems 115
 tract 106, 110
Gene(s) 9, 25, 67, 81, 93, 95, 96, 146, 149,
 153, 155, 156, 162, 164, 166, 167, 168
 cytokine 25
 divergent immune-related 81
 expression 9, 93, 95, 96, 146, 149, 153, 156,
 162, 164, 168
 proinflammatory 155
 repression 167
 restricting 166
 silencing 155
 transcription 67, 153
Glial fibrillary acidic protein (GFAP) 19, 23
Glycogen synthase kinase (GSK) 187
Glycoprotein 23
Gut 96, 97, 110, 111, 113, 119, 120, 122
 brain communication 96
 dysbiosis 110, 111, 119, 120
 homeostasis 113
 hormone secretion 97
 metabolites 119
 microbes 96, 110, 119, 120, 122
 microbial communities 96
 microorganisms 97, 119
Gut bacteria 53, 97, 109, 112, 118, 119, 121,
 122, 123, 124
 reactivate 121
Gut microbiome 94, 95, 104, 105, 106, 107,
 108, 109, 110, 111, 112, 119, 120, 121,
 122
 composition 95
 dysbiosis 107
 metabolites for neuroprotection 121

Gut microbiota 35, 52, 106, 107, 115, 120,
 123, 125, 126
 and neurodegenerative disease 106
 communications 107
 composition 115, 123, 125, 126
 healthy 120
 hypothesis 35, 52

H

Haematopoiesis 148, 149
HD 74, 193
 motor symptoms 193
 neuroinflammation 74
HDAC inhibitors (HDACi) 153, 154, 170,
 171, 172
Hippocampus synaptic function 56
Homeostasis 5, 19, 21, 44, 72, 93, 96, 105,
 107, 109, 124, 150, 180
 cerebral 150
 immune system's 96
 immunological 109
 intestinal 93, 109
 lipid 124
Hormones 107, 109, 110, 121
 adrenocorticotropic 109
Human neuron-derived teratocarcinoma 199

I

Illnesses, neurological 9, 37, 45, 48, 84, 92,
 105, 128
Immune signaling 109
Immunogenicity 81
Immunological responses 9, 33, 77, 94
Immunomodulatory drugs 65, 79
Immunopathogenesis of gut microbiota
 hypothesis 35, 52
Immunopathogenic neurodegenerative disease
 hypotheses 34
Immunotherapies-mediated progression 84
Impaired cortical cholinergic
 neurotransmission 53
Inflammation 17, 18, 24, 33, 34, 48, 49, 50,
 71, 76, 77, 80, 94, 113, 153, 154, 155
 and inflammatory reactions start 77
 combat 80
 intestinal 94
 microglia-induced 153

Subject Index

Inflammatory 50, 51, 67, 71, 74, 75, 81, 91, 119
 bowel disease (IBD) 119
 mediators 51, 67, 71, 74, 75, 81
 reactions 50, 91
Injury, traumatic brain 48, 156
Insulin sensitivity 197
Intestinal barrier dysfunction 95
Irritable bowel syndrome (IBS) 119

J

Jakob disease 10

L

Lambert-Eaton myasthenic syndrome 199
Lewy body dementia (LBD) 115
Lipopolysaccharide injection 25
LPS-induced 25, 123, 154
 inflammation 154
 neuroinflammation 25
 stroke 123

M

MAPK pathway 199
MAPT mutations 115
Mechanisms 26, 37, 38, 44, 69, 72, 84, 91, 110, 127, 151, 155, 171, 200
 chaperone refolding 44
 cytoprotective 44
 dialysis 127
 immunological 26
Medications 162, 199
 anti-inflammation 199
 epigenetics-based 162
Metabolic syndrome 33
Metabolites 72, 89, 95, 96, 105, 106, 110, 112, 119, 123
 bacterial polyphenolic 123
 toxic 72
Metal dyshomeostasis 2
Metastatic renal cell carcinoma 184
Microglia 73, 149, 151
 interactions 73
 phagocytose 151
 transformed 149

Advances in Diagnostics and Immunotherapeutics 223

Microglial 11, 18, 20, 22, 23, 25, 69, 75, 78, 107, 147, 150, 152, 154, 156
 activation 18, 20, 22, 23, 69, 75, 78, 147, 150, 154, 156
 activity 107, 152
 dysfunction 25, 147
 fractalkine receptor 25
 mediated phagocytosis 11
Microtubule assembly process 39
Migration inhibitory factor (MIF) 51
Monocyte(s) 49, 70, 93
 chemoattractant proteins (MCPs) 49, 70
 inflammatory 93
Motor 4, 5, 7, 21, 47, 77, 92, 95, 110, 112, 113, 114, 116, 170, 182, 188, 189, 190, 192, 193, 197, 198, 199, 200, 201
 abnormalities 188, 192
 defects 189
 dysfunction 21, 197
 function 5, 110
 neuron activity 201
 neuron degeneration 5, 198, 200
 neurons 4, 5, 95, 114, 199
 proteins 47
 symptoms 92, 95, 112, 113, 182, 188
Multiple sclerosis (MS) 23, 45, 48, 91, 98, 104, 110, 113, 114, 117, 196
Mutations, heteroblastic 12

N

Nausea 54, 112, 179
Nerve growth factor (NGF) 150
Nervous system 1, 6, 47, 91, 105, 106, 109, 118, 120, 146
 autonomic 105, 109
 disorders 1
Neurodegeneration disease 11
Neurodegenerative 5, 33, 40, 47, 83, 88, 92, 115, 169, 170
 conditions 5, 33, 47, 88, 92, 115, 170
 dementias 40
 disorders, autosomal dominant progressive 83
 disorders treatment 169
Neurodegenerative illnesses 1, 4, 6, 8, 9, 33, 34, 38, 40, 42, 44, 46, 47, 48, 96, 97, 98
 lethal inherited 96
 multifactorial 4
Neurogastroenterology 91

- Neuroimaging techniques 49
Neuroinflammatory 17, 18, 19, 21, 24, 35, 48
 hypothesis 35, 48
 responses 17, 18, 19, 21, 24
Neurological 45, 54, 77, 84, 91, 97, 104, 108,
 110, 115, 128, 152, 164, 171, 177, 197,
 204
 diseases 54, 104, 108, 110, 164, 197
 disorders 45, 77, 84, 91, 97, 115, 128, 152,
 171, 177, 204
Neuronal injury 9, 21
Neurons 3, 8, 18, 20, 21, 37, 41, 47, 48, 50,
 52, 67, 72, 75, 111, 122, 151, 152, 165,
 177
 damages 67
 disease-associated 165
Neuropathological sicknesses 51
Neuroprotection 119, 121, 124, 171, 181, 187,
 198
Neuroprotective 20, 25, 50, 121, 123, 153,
 154, 171, 189, 194, 203
 agent 25, 194
 effects 20, 50, 121, 123, 153, 154, 171,
 189, 203
Neurotrophins dysfunction 32
Nuclear factor (NF) 20, 109
- O**
- Oxidation-reduction reactions 121
Oxidative stress 10, 52
 immune-mediated 52
 peroxide-mediated 10
- P**
- Pain, neuropathic 45
Parkinson disease 116
Pathologies 22, 183
 neurodegenerative 22
 neurofibrillary 183
Pathways 12, 35, 38, 46, 47, 52, 65, 69, 70,
 88, 89, 96, 120, 122, 123, 181, 185, 190,
 193
 inflammatory 46, 69
 mesolimbic 193
 metabolic 88, 122
 neurological 120
 neuronal health 12
 neurotrophic 47
 protein kinase 123
Peripheral nerve systems (PNS) 70, 71, 74, 83
Phagocytosis 55, 69, 72, 150, 155, 183
Phenotypes 21, 49, 52, 113, 147, 150, 155,
 183
 degenerative 183
 immature neuronal 52
 inflammatory 155
 proinflammatory 21
Phosphorylation, tyrosine kinase 181
Plasticity 38, 153, 185
 neuronal 153
Positron emission tomography (PET) 4, 68
Pro-inflammatory cytokines mediators 119
Problems 43, 94, 115
 gastrointestinal 94, 115
 neurological 43
Processes 33, 49, 69, 76, 89, 111, 119, 120,
 149, 163, 178
 immunopathological 33
 inflammatory 49, 76, 111, 178
 metabolic 89, 119, 120
 neurodegenerative 69
 neuropathological 163
 transformative 149
Progressive neurodegenerative complication
 65
Proinflammatory 21, 50, 52, 67, 70, 75, 76,
 109, 116, 151
 cytokines 21, 50, 52, 67, 70, 109, 116, 151
 macrophages 75
 reaction 76
Properties 36, 51, 83, 121, 123, 189, 194
 anti-inflammatory 189
 disease-alleviating 83
 neuroprotective 121, 123, 194
 pro-inflammatory 36
Protein(s) 18, 20, 24, 25, 35, 36, 37, 41, 43,
 44, 46, 49, 67, 70, 81, 83, 121, 164, 167,
 178, 185
 aggregation 36, 46, 67, 178
 amyloid precursor 35, 36, 37, 41, 185
 anti-inflammatory 25
 complementary 20
 degradation 43
 deposition 37
 fusion 24
 heat shock 46
 homeostasis 164

Subject Index

inflammatory immune 83
innate immune 70
misfolding and endoplasmic reticulum stress
41
monocyte chemoattractant 18, 49
oxidation 44, 121
translation 167
transmembrane signaling 81
Proteinopathies, neurodegenerative 110

R

Reactive oxygen species (ROS) 7, 9, 17, 19,
44, 45, 46, 56, 118, 146, 152
Receptor tyrosine kinase (RTKs) 25, 47, 180,
181
Relapsing-remitting multiple sclerosis
(RRMS) 113, 114, 196
Repetitive nerve stimulation (RNS) 8, 9
Respiration, mitochondrial 44
Reverse 182, 203
synaptic dysfunction 182
transcriptase 203
Rheumatoid arthritis 120, 199
Risk factors, genetic 35
RNA metabolism and autophagy 47

S

Schizophrenia 10, 45, 91, 193, 194
Signaling 22, 25, 121
neurodegenerative 22
pro-inflammatory microglial 25
steroid hormone 121
Signaling pathways 18, 20, 42, 45, 46, 47, 89,
106
immunological 89, 106
Spastic paraparesis and sphincter dysfunction
113
Spinal 2, 3, 154, 177, 178, 197, 198, 199, 200
cord injury 154
muscular atrophy (SMA) 2, 3, 177, 178,
197, 198, 199, 200
Sporadic amyotrophic lateral sclerosis (SALS)
11
Stress 6, 8, 42, 43, 44, 47, 53, 67, 69, 91, 120
oxidative-nitrosative 67, 69
related conditions 120
shock responses 47

Advances in Diagnostics and Immunotherapeutics 225

Synaptic 24, 37, 111, 186
dysfunction 111
maturation 24
protein 37
transmission 186

T

Tau protein 4, 37, 38, 39, 40, 51, 53, 54, 55,
169, 182, 183
hyperphosphorylated 4, 39, 54, 169
phosphorylation 40, 53, 183
Therapies, microbiome-based 88, 98
Transcription factors 76, 148, 153, 168
Transcriptional dysregulation 171
Treatment 44, 93, 97, 98, 112, 125, 126, 156,
157, 162, 163, 164, 170, 171, 172, 181,
193, 203
antibiotic 125, 126
antioxidant 44
Tumor necrosis factor (TNF) 21, 24, 33, 50,
51, 70, 76
Tyrosine kinase inhibitors (TKIs) 181, 189,
202

V

Vascular endothelial growth factor (VEGF)
150, 182
Vomiting 54, 179

“WISDOM IS NOT A PRODUCT OF SCHOOLING BUT THE LIFELONG ATTEMPT TO ACQUIRE IT “

Albert Einstein



Anuradha Mishra

Anuradha Mishra is presently working as professor & Director, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow. She has rich experience on pharmacological screening of drugs for various disorders like neurodegenerative, gastric ulcers, cancer, etc. She has 18 years of teaching and research experience. She has published 72 research papers in National and International journals. She has published 2 books with International Publishers. She has received research grants from CST-UP. She has published various book chapters including Springer publishers. Currently she is involved in targeting brain and neurological disorders and possible therapeutic or preventive approaches to reduce the disease advancement. She supervised 10 PhD and 20 PG scholars so far.



Preeti Bajpai

Preeti Bajpai is presently working as Associate Professor in the Department of Zoology, Mahatma Gandhi Central University, Motihari, Bihar. Dr. Bajpai is a goal-oriented professional with more than 20 years of spearheaded academic and research experience on immunological aspects of vector borne parasite diseases, metabolic and neurological disorders. Moreover her lab has been actively involved in designing novel immunomodulators of synthetic or natural origin drug and vaccine delivery nano vehicles as an ameliorative approach towards disease. Her research work has been acclaimed by DST, SERB and ICMR in the form of extramural grant of more than 2.5 crores. Dr. Bajpai has 70 research articles in International journals of high repute, 11 book chapters with International publishers and nine national and International awards to her credits. Furthermore, she has also supervised more than 15 PhD scholars and 100 post graduate dissertations. Her current research work spheres around the exploration of epigenetic factors regulating immunological pathways in neurodegenerative disorders.



Tarique Mahmood Ansari

Tarique Mahmood Ansari is a Professor in the Department of Pharmacy, Integral University, Lucknow having more than 15 years of Experience in Teaching, Research & Pharmaceutical Industry. His subject and field of technical / Research expertise are Pharmacological screening of herbal drugs & formulations, cardiovascular diseases, Dyslipidemia, Diabetes and Obesity and Advance cardiovascular pharmacology. He is Principal Investigator (PI) of an EMR project sanctioned by Ministry of AYUSH, Govt. of India. He Supervised around 50 M. Pharm. Dissertation work as Supervisor/ co-supervisor and 6 Ph.D. Research scholars and 8 Ph.D. Research scholars are enrolled. He has Published more than 100 Research/Review papers and more than 50 Abstracts in various International / National journals of high repute with a cumulative impact factor of more than 60. He has Participated in more than 70 International / National conferences as Delegate/ Key person/ Organizing Committee member. He has been Awarded by Many Government and Non-Government Bodies like Ministry of Ayush, Prisal Foundation, APTI, Ad Scientific Indexing, Bentham Science.